Oncolytic herpes viruses are attenuated, replication-competent viruses that selectively infect, replicate within, and lyse cancer cells and are highly efficacious in the treatment of a wide variety of experimental cancers. The current study seeks to define the pharmacologic interactions between chemotherapeutic drugs and the oncolytic herpes viral strain NV1066 in the treatment of pancreatic cancer cell lines. The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor cell) ranging from 0.01 to 1.0 with or without 5-fluorouracil (5-FU) or gemcitabine. Synergistic efficacy was determined by the isobologram and combination-index methods of Chou and Talalay. Viral replication was measured using a standard plaque assay. Six days after combination therapy, 76% of Hs 700T cells were killed compared with 43% with NV1066 infection alone (MOI 5 0.1) or 0% with 5-FU alone (2 mmol/L) (P ! .01). Isobologram and combination-index analyses confirmed a strongly synergistic pharmacologic interaction between the agents at all viral and drug combinations tested (LD 5 to LD 95 ) in the three cell lines. Dose reductions up to 6-and 78-fold may be achieved with combination therapy for NV1066 and 5-FU, respectively, without compromising cell kill. Pancreatic cancer is an aggressive malignancy that is the fourth leading cause of cancer-related deaths for both men and women in the United States.
Pancreatic cancer is an aggressive malignancy that is the fourth leading cause of cancer-related deaths for both men and women in the United States. 1, 2 In 2005, adenocarcinoma of the exocrine pancreas will account for an estimated 31,860 new cases and 31,270 deaths. 1 Despite the recent advances in anticancer drugs, surgical resection remains the only potentially curative option for patients with pancreatic cancer. Only 10-15% of patients, however, are resectable at the time of diagnosis. 3 Moreover, survival after presumed curative resection remains poor with median survivals ranging from 17 to 21 months. [3] [4] [5] [6] [7] [8] For patients with distant disease or locally advanced disease precluding resection, the prognosis is worse with median survivals ranging from 3 to 10 months. 2 A multitude of therapeutic regimens using chemotherapeutic agents and radiation have been investigated. While 5-fluorouracil (5-FU)-and gemcitabine-based regimens have demonstrated the greatest antitumor effect, only negligible improvements in survival have been realized. It is clear that novel therapeutic options are needed for the treatment of pancreatic cancer.
Oncolytic herpes viruses are attenuated, replication-competent herpes simplex type 1 viruses (HSVs) that selectively infect, replicate within, and lyse cancer cells. These viruses have been shown to be highly efficacious in the treatment of a wide variety of human and animal cancers. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Recent studies in our laboratory and others suggest that the efficacy of oncolytic HSV is enhanced when administered in combination with ionizing radiation or chemotherapeutic agents. 12, [19] [20] [21] [22] This observation is not universal, however, depending on both the chemotherapeutic agent or viral strain used and the individual cancer. Combined modality therapeutic regimens are attractive as they aim to exploit a synergistic interaction between two agents to maximize efficacy and reduce treatment-associated toxicity and the development of drug resistance. As we envision combining oncolytic HSV with current chemotherapeutic regimens for the initiation of human clinical trials, this study sought to investigate whether 5-FU or gemcitabine potentiates efficacy of oncolytic HSV in the treatment of pancreatic cancer.
MATERIALS AND METHODS Cells
The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were obtained from the American Type Culture Collection (Rockville, MD) and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with high glucose, 1.5 g/L sodium bicarbonate, 100 U/ml penicillin, 100 mg/ ml streptomycin, and 10% fetal calf serum. Vero cells (American Type Culture Collection, Rockville, MD) were grown in minimum essential medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal calf serum. Cells were maintained in a 5% CO 2 humidified incubator at 37 C.
Virus
NV1066 is an attenuated, replication-competent oncolytic HSV whose construction has been previously described. 23, 24 Briefly, NV1066 is derived from the wild-type HSV-1 virus (F strain) and is rendered safe via deletions in the viral replicative and virulence genes ICP0, ICP4, and g 1 34.5. NV1066 is a derivative of the oncolytic HSV strain NV1020, which has already been tested in human phase I clinical trials demonstrating a favorable safety profile. 25 Viral stocks were propagated on Vero cells and titered by standard plaque assay. 17 
Cytotoxicity Assay
Cytotoxicity assays were performed by plating 2 3 10 4 cells into 24-well flat-bottom assay plates (Becton Dickinson, Franklin Lakes, NJ) in 1 ml of media. After overnight incubation at 37 C, cells were treated with either media alone (control), 1-4 mmol/L 5-FU (American Pharmaceutical Partners, Schaumburg, IL), 0.5-2 nmol/L gemcitabine (Eli Lilly and Company, Indianapolis, IN), or NV1066 at multiplicities of infection (MOI, the ratio of viral plaque-forming units [PFU] to tumor cell) ranging from 0.01 to 1.0. Combination therapy experiments were performed by first exposing cells to either 5-FU or gemcitabine for 6 hours. After exposure, the media containing the chemotherapeutic agent was removed, cells were washed with phosphatebuffered saline (PBS), and fresh medium was added. Cells were then infected with NV1066 diluted in 100 ml media and incubated at 37 C. Daily after infection, media was removed and cells were lysed with 1.35% Triton-X solution to release intracellular lactate dehydrogenase (LDH). LDH was then quantified with the Cytotox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI) that measures conversion of a tetrazolium salt into a red formazan product. Absorbance was measured at 450 nm with a microplate reader (EL321e; Bio-Tek Instruments, Winooski, VT). Results are expressed as the surviving percentage of cells as determined by the measured absorbance of each sample relative to control, untreated cells. All samples were tested and experiments were replicated, in triplicate.
Quantitative Analysis of Synergy
The isobologram and combination-index (CI) methods, derived from the median-effect principle of Chou and Talalay, were used to define the pharmacologic interaction between the chemotherapeutic drugs and NV1066. 26 Details of these equations and of the software used to perform the computerized analyses have been described previously. [26] [27] [28] [29] [30] Briefly, by taking into account the potency of the individual drugs, the potency of the combination of the drugs, and the shapes of their dose-effect curves, these methods enable the precise analysis of the pharmacologic interaction of two-drug combinations by comparing observed drug effects with predicted additive drug effects.
Data obtained from the cytotoxicity experiments were used to perform these analyses. The isobologram method is a graphical representation of the pharmacologic interaction and is formed by selecting a desired fractional cell kill (Fa) and plotting the individual drug and viral doses required to generate that Fa on their respective x-and y-axes. A straight line is then drawn to connect the points. The observed dose combination of the two agents that achieved that particular Fa is then plotted on the isobologram. Combination data points that fall on the line represent an additive drug-drug interaction, whereas data points that fall below or above the line represent synergism or antagonism, respectively.
The CI method is a mathematical and quantitative representation of a two-drug pharmacologic interaction. Using data from the cytotoxicity experiments and computerized software, CI values are generated over a range of Fa levels from 0.05 to 0.95 (5-95% cell kill). CI of 1 indicates an additive effect between two agents, whereas a value of CI ! 1 or CI O 1 indicates synergism or antagonism, respectively. More clinically pertinent, data generated from the CI method can be used to quantify the dose-reduction index (DRI) for the combination of two drugs. DRI represents the fold-decrease of each individual agent attainable if the two drugs are used in combination as opposed to alone to achieve a particular Fa.
Viral Replication Assay
Standard plaque assays were performed to quantify viral proliferation within pancreatic cancer cells. Cells (2 3 10 4 ) were plated in 12-well flat-bottom assay plates in 2 ml of media. After overnight incubation at 37 C, cells were treated with NV1066 alone (MOI 5 0.01) or in combination with 5-FU (1-5 mmol/L) or gemcitabine (1-5 nmol/L). Supernatants and cells were collected from culture wells 6 days following treatment. Samples were subjected to three freeze-thaw lysis cycles to release intracellular viral particles. Serial dilutions of supernatants and cell lysates were cultured on confluent layers of Vero cells and viral titers were determined by counting viral plaques 72 hours later. All samples were tested, and experiments were replicated, in triplicate.
Real-Time Reverse Transcriptase
Polymerase Chain Reaction Quantification of GADD34 Expression Cells (3 3 10 5 ) were plated in six-well plates with 2 ml of media, incubated overnight, and treated with 5-FU (10 mmol/L) or vehicle alone (control). Six hours following exposure, medium was removed, cells were washed with PBS, and fresh medium was added. Cells were harvested 12, 24, 36, and 60 hours after exposure and total RNA was isolated using an RNeasy Mini Kit (Qiagen Inc, Valencia, CA). SYBR green-based real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). The following primers were used: GADD34 forward (5#-GGAGGAAGAGAATCAAGCCA-3#), GADD34 reverse (5#-TGGGGTCGGAGCCT GAAGAT-3#), 18S forward (5#-GTAACCCGTT GAACCCCATT-3#), and 18S reverse (5#-CCATC CAATCGGTAGTAGCG-3#). Co-amplification of the 18S ribosomal RNA housekeeping gene was used to normalize the amount of total RNA present. Thermal cycling conditions for amplification of GADD34 were as follows: 95 C for 9 minutes and 30 seconds; 40 cycles of 94 C for 30 seconds, 55. 6 C for 30 seconds, 72 C for 30 seconds, and 78 C for 30 seconds.
Statistical Analysis
All data are expressed as mean 6 SEM. Twotailed Student's t test was used to determine significance between treatment groups.
RESULTS

Cytotoxicity of NV1066 in the Treatment of Hs 700T Human Pancreatic Cancer Cells
To examine the oncolytic efficacy of NV1066, dose-dependent cytotoxicity experiments were performed. NV1066 demonstrates dose-dependent cytotoxicity against the Hs 700T human pancreatic cancer cell line (Fig. 1) . Cell kill progressively increases for the duration of the experiment at all doses tested. Seven days following infection at an MOI of 1.0, 90 6 0.3% of cells were killed (P ! .01). Even at 10-and 100-fold lower MOIs of 0.1 and 0.01, 84 6 1% and 63 6 3% of cells were killed 7 days following infection, respectively (P ! .01).
Cytotoxicity of Combination NV1066 and 5-Fluorouracil or Gemcitabine
To examine the cytotoxic effect of combining chemotherapeutic agents and NV1066, Hs 700T cells were treated with either 5-FU or gemcitabine alone, NV1066 alone, or a combination of a 5-FU or gemcitabine and NV1066. Treatment of Hs 700T cells with 2 mmol/L 5-FU alone or NV1066 at an MOI of 0.1 alone resulted in 0 6 1% and 43 6 3% cell kill, respectively, 6 days following treatment (Fig. 2, A) . The expected cytotoxicity of combining treatments assuming an additive pharmacologic interaction was calculated and plotted ( Fig. 2 , A, dotted line). Observed cytotoxicity with combination 2 mmol/L 5-FU and NV1066 at an MOI of 0.1 demonstrated 76 6 4% cell kill 6 days after treatment and is significantly greater than predicted cell kill (P ! .01).
Similar results were obtained combining gemcitabine and NV1066. Six days following treatment of Hs 700T cells with 1 nmol/L gemcitabine alone or NV1066 at an MOI of 0.1 alone, 3 6 3% and 45 6 5% of cells were killed, respectively (Fig. 2, B) . Observed cytotoxicity with combination gemcitabine and NV1066 at the same doses demonstrated 71 6 3% cell kill and is significantly greater than predicted cell kill (P ! .01). Synergism was observed over a range of clinically achievable doses of both 5-FU (Fig. 3 , A-C ) and gemcitabine ( Fig. 3 , D-F ). Synergism was also observed in the treatment of PANC-1 and MIA-PaCa-2 human pancreatic cancer cell lines (data not shown).
Quantitative Analysis of Synergy
The isobologram and CI methods developed by Chou and Talalay were used to confirm and quantify the synergism observed between the chemotherapeutic drugs and NV1066. Isobolograms were constructed for Fa values ranging from 0.5 to 0.95 (5-95% cell kill). Experimental combination therapy data points plot well below the expected additive line at each Fa value for both combinations indicating strong synergism across a broad range of doses and agents. Representative isobolograms are shown in Figure 4 .
CI values for the interaction between 5-FU and NV1066 (0.25-0.47) and gemcitabine and NV1066 (0.10-0.53) are !1 over the entire range of Fa values tested (0.05-0.95), indicating strong synergism (Table 1). Using these data, the DRI was then calculated for each Fa value. For combination 5-FU and NV1066, compared with either drug alone, up to 78-fold and 6-fold dose reductions can be achieved, respectively, without compromising cell kill (Table  2) . For combination gemcitabine and NV1066, up to 207-fold and 10-fold dose reductions can be achieved, respectively, without compromising cell kill (Table 3 ). These mathematical methods therefore demonstrate a strong synergistic interaction between each chemotherapeutic drug and NV1066 over a wide range of therapeutic doses and cytotoxic effect levels.
Viral Replication Assay
Viral progeny production in Hs 700T cells was quantified in the absence or presence of 5-FU or gemcitabine using standard plaque assays ( 6 PFU, and 8 3 10 5 PFU, respectively, 6 days following infection (Fig. 5, A) . This represents a 750-to 5500-fold amplification of the initial infecting viral dose (200 PFU) and a 3-to 19-fold increase in viral titer production compared with cells treated with virus alone (P ! .05). Combination therapy with gemcitabine resulted in a 2800-to 8000-fold amplification of the initial infecting viral dose representing a 10-to 30-fold increase in viral progeny compared with infection with NV1066 alone (P ! .01) (Fig. 5, B) .
Real-Time Reverse Transcriptase Polymerase Chain Reaction Quantification of GADD34 Expression
Real-time RT-PCR was used to assess genetic expression of the cellular stress response gene GADD34 following treatment of pancreatic cell lines with 5-FU. Six-hour exposure of Hs 700T cells to 5-FU resulted in a 2.3-fold upregulation of GADD34 mRNA expression 24 hours following treatment (p ! .01) (Fig. 6 ). 
DISCUSSION
Novel therapies are desperately needed for the treatment of pancreatic cancer. Current chemoradiation-based therapeutic regimens are largely limited in both efficacy and toxicity. Oncolytic herpes viruses are attenuated, replication-competent viruses that selectively infect, replicate within, and lyse cancer cells and are highly efficacious in the treatment of a wide variety of experimental therapies. We have previously shown that oncolytic herpes viruses are effective as a single-agent in the treatment of an experimental model of pancreatic cancer. 14 We now use the isobologram and CI methods of Chou and Talalay to define the pharmacologic interactions between 5-FU, gemcitabine and the oncolytic HSV strain NV1066 and demonstrate a synergistic enhancement in cytotoxicity in the treatment of a human pancreatic cancer cell line. 26 Synergism was observed across a range of clinically achievable doses of two of the most effective and widely used chemotherapeutic agents in the treatment of this disease.
Furthermore, synergism was observed in the treatment of all three cell lines tested although representative data from one cell line is shown.
A fundamental advantage of oncolytic viral therapy compared to standard cancer treatment modalities, is the in vivo amplification of the administered viral dose. Following completion of the viral life cycle in a cancer cell, cellular lysis results in the release of many new infectious viral particles which can then infect additional viable cancer cells. We demonstrate that the production of viral progeny is significantly enhanced in the presence of either 5-FU or gemcitabine. Our data also suggest that this potentiation of viral replication is responsible for the synergism observed. The differential improvement in cell kill in the combination therapy arms of the experiments does not appear to be an initial cytotoxic effect. Rather, it becomes evident five to six days following treatment after several viral life cycles have been completed and after the differential increase in viral progeny production is evident by plaque assay. This amplification is limited only to the extent that viable cancer cells are present to support viral replication.
Several molecular mechanisms have been proposed to explain the potentiation of viral replication by chemotherapy and radiation therapy. 11,12,19-22, 31,32 These mechanisms describe viral exploitation of the host cellular stress response following exposure to chemotherapeutic agents or ionizing radiation. Previous work in our laboratory has demonstrated that upregulation of host cellular ribonucleotide reductase (RR) following exposure of cancer cells to ionization radiation enhances viral replication and cell kill in the treatment of a colorectal cancer cell line. 21 RR reduces ribonucleotides to deoxyribonucleotides and is responsible for the production of the substrates of DNA synthesis. These studies were performed using the second-generation oncolytic herpes simplex type-1 viral strain G207, which has an insertional inactivation of the large subunit of the viral ribonucleotide reductase gene and is therefore dependent on host cell RR for viral replication. Upregulation of host cell RR following DNA damage has therefore been proposed to complement the viral genomic deletion enhancing viral replication.
In comparison to G207, NV1066 is not deficient for viral RR and is therefore not dependent on host cell RR for viral replication. More recent work from our laboratory has shown that upregulation of the host cellular stress response gene GADD34 (Growth Arrest and DNA Damage Protein 34) mediates a synergistic cytotoxic effect following exposure of gastric cancer cells to mitomycin C. 22 GADD34 is homologous to the viral replicative gene g 1 34.5dboth copies of which are deleted in NV1066 for attenuation. Upregulation of GADD34 following exposure to the chemotherapeutic agent therefore complements this viral genomic deletion and enhances viral replication. We similarly demonstrate upregulation of GADD34 following exposure of Hs 700T cells to 5-FU.
The clinical implications of this synergism are evident and are not limited to enhanced efficacy. The DRI, the most relevant clinical parameter derived from the Chou and Talalay analysis, reveals the potential for significant dose reductions without compromising cell kill. Dose reductions minimize treatment-associated toxicity, thereby improving the tolerability of therapeutic regimens and quality of life.
The use of these agents alone or in combination with systemic chemotherapy can be conceivably used in several clinical settings. The retroperitoneal resection margin is the site of local failure in up to 50% of cases following pancreaticoduodenectomy. 2 Oncolytic HSV could be administered intraoperatively into the tumor bed following resection for clearance of microscopic residual disease and sterilization of this difficult margin. Locally advanced primary disease precluding resection could be approached with percutaneous or endoscopically administered virus in combination with neoadjuvant systemic chemotherapy in an attempt to downstage disease and permit subsequent curative resection. Additionally, common sites of recurrent metastatic disease include the peritoneal cavity and liver, which could be treated with regional intraperitoneal or intrahepatic arterial perfusion, respectively. The toxicity of these agents has also been extensively investigated in both animal models and humans. Oncolytic herpes viruses are highly specific for infection of cancer cells, sparing normal cells. The safety of these oncolytic viruses has been tested in preclinical toxicology studies in Aotus monkeys, which are extremely sensitive to wild-type herpes viral infections. These monkeys demonstrated no toxicity when administered attenuated virus. 33, 34 Viral dissemination following administration has been extensively investigated in our laboratory using both quantitative PCR detection of the viral gene ICP0 and radiolabeled herpes virus. These studies repetitively demonstrate no viral proliferation in noncancerous tissues. Finally, the safety of use of several oncolytic HSV strains has been demonstrated in humans with the recent completion of several phase I clinical trials. 25 
CONCLUSION
We demonstrated that 5-FU and gemcitabine potentiate oncolytic herpes viral replication and cytotoxicity across a range of clinically achievable doses in the treatment of human pancreatic cancer cell lines. The clinical implications of this synergistic interaction are paramount and include improvements in efficacy, treatment-associated toxicity, tolerability of therapeutic regimens, and quality of life. This data also corroborate prior studies suggesting a synergistic interaction between chemotherapy and oncolytic viral therapy and support the commencement of clinical trials incorporating oncolytic herpes viruses into investigative therapeutic regimens in the treatment of pancreatic cancer. 
Discussion
Dr. Ravi Chari (Nashville, TN): Dr. Eisenberg, I would like to congratulate you and Dr. Fong on another excellent presentation, which continues a line of investigation with regard to oncolytic virus in the management of hepatobiliary malignancy. Your presentation was very thoughtful, but I must tell the membership that the paper is even more impressive and I enjoyed reading it and it provided a lot more information beyond what you showed today. I look forward to its publication. I have the following questions.
The first question centers on the virus selection. In both your presentation and manuscript you indicate that you selected NV1066. Previous work in hepatobiliary malignancy and specifically colorectal metastases to the liver has centered on NV1020. Could you outline the reasons why 1066 was chosen instead of 1020?
The second question has to do with your time-line of increased expression of GADD34. With regard to a clinical model or a more clinical appropriate scenario, administration of chemotherapy would probably follow viral administration. What impact would the rapid but short induction of this GADD34 have in a clinically relevant model where 5-FU is administered several weeks or days after the virus itself?
And finally, while you also just touch on it in your paper, I would ask you also to say in the scenario of clinical management of pancreatic cancer, how would you envision the use of NV1066?
Again, I enjoyed this presentation and paper and thank you.
Dr. Eisenberg: Thank you, Dr. Chari, for your kind comments. If I may answer your final question first, there are many clinical settings in which we can envision using these viruses in the treatment of patients with pancreatic cancer. In the preoperative setting, we can target patients with locally advanced disease where resection is not possible, delivering the virus directly into the tumor either via a percutaneous route under CT guidance or endoscopically with the hope of downstaging these patients to ultimately achieve a potentially curative resection.
Regarding intraoperative delivery, we have heard extensively this week that the retroperitoneal resection margin following pancreaticoduodenectomy is problematic and is the site of local recurrences in a significant percentage of patients. Virus could be delivered locally into the retroperitoneum following resection of the pancreas in an attempt to sterilize this difficult margin.
Finally, these viruses could be administered in the adjuvant setting either regionally or systemically. As we have already heard this morning, recurrence patterns frequently involve the peritoneal surface and the liver. Both of these sites can be targeted regionally by delivery of virus into the peritoneal cavity or hepatic artery, respectively, and both routes have already been shown to be efficacious in experimental models of cancer in our laboratory.
Regarding your second question, these experiments were conducted by first briefly exposing cancer cells to a very low dose of 5-FU. What followed was GADD34 mRNA upregulation peaking at 24 hours and then falling off. We know from recent experiments in our laboratory that the protein level of GADD34, which is more accurately what we hypothesize the virus is exploiting resulting in the synergy that is observed, is upregulated well beyond that and at least out to 72 hours. As such, this work may favor administering chemotherapeutics prior to the delivery of virus. That being said, as long as there are viable, replicating viral particles within the tumor at the time of administration of chemotherapeutics, regardless of whether it is before or after viral administration, virus may be able to exploit the induced cellular stress response in cancer cells.
Finally, regarding the use of NV1066 versus NV1020, while we investigate many herpes viral strains in our laboratory, most of our experience is with G207 and NV1020, NV1020 being the strain that we used in our phase I clinical trial in patients with colorectal liver metastases. Using these viruses we have demonstrated synergy with mitomycin C in a gastric cancer cell line and with radiation in a colon cancer cell line. This synergism, however, is not universal in that it is not seen with some other cancer cell lines and other chemotherapeutic agents. So we used this opportunity to further explore to what extent this synergism exists across the range of our viruses. Additionally, NV1066 carries the enhanced green fluorescent protein transgene, which will enable us to track infection and monitor vector spread as we further investigate these pharmacologic interactions in vivo.
Dr. Mark Callery (Boston, MA): With respect to the clinical scenario, what would you see as the most likely reason why this would fail going forward? And also, I didn't fully understand the importance of the elongation and initiation factor. Are you trying to achieve a global translational repression of protein synthesis as part of the cell kill? Dr. Eisenberg: Initial clinical trials demonstrated the safety and efficacy of direct local injection of these agents into tumors. After that, Dr. Fong was the first to inject these viruses into the bloodstream and showed that it was safe. Immunity was an initial concern considering that 90% of adults have circulating antibodies to the herpes virus. But animal studies looking at viral uptake and efficacy in preimmunized animals showed negligible attenuation when administered systemically versus regionally.
We are unbelievably excited about these viruses, but just as with any other anticancer agent, tumors are heterogeneous and tumor cells are very clever, and they certainly may find their way around these viruses just as they do chemotherapy and radiation. That being said, up to today, after testing over 110 cell lines in our laboratory, we have really found only several cell lines that are highly resistant.
With respect to the initiation factor, following a herpes viral infection, the host cell tries to shut off its own protein synthesis so the virus can no longer use that machinery to replicate. It does this by phosphorylating the alpha subunit of an initiation factor called eIF-2. Wild-type virus counters this defense mechanism by dephosphorylating that initiation factor which is a result of the viral gene gamma-1 34.5 and enables host cell protein synthesis and viral replication. NV1066, however, is attenuated by deletion of gamma-1 34.5. GADD34 is a host cell DNA repair enzyme that is highly homologous to viral gamma-1 34.5. So, we are trying to enhance viral replication by cancer cell-specific induction of GADD34 to bypass the viral attenuating deletion. Dr. Eisenberg: There are other pathways that we have looked at, and yes, essentially we are trying to modify these cancer cells to make them even more sensitive than they already are to these agents. In an earlier study, we looked at the gene ribonucleotide reductase. Ribonucleotide reductase is involved with the synthesis of DNA building blocks, the viral counterpart of which is deleted from the G207 virus for attenuation. We know that ribonucleotide reductase is upregulated following radiation of cancer cells which may benefit G207 viral replication in much the same way that GADD34 benefits NV1066. NV1066, however, doesn't have a mutation of ribonucleotide reductase and therefore isn't dependent
